On July 31, 2025, Salarius Pharmaceuticals reported an expected net loss of about $900,000 for Q2 2025 and approximately $800,000 in cash, following an issuance of shares that raised $3.8 million. Post-issuance, they estimate about $4.5 million in cash available for operations.